Which has stronger valuation & earnings, CRVO or PEPG?

CervoMed has higher revenue and earnings than PepGen. PepGen is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CervoMed $4.01M 9.41 -$26.97M -$3.28 N/A PepGen N/A N/A -$89.65M -$1.75 N/A

Is CRVO or PEPG more profitable?

PepGen has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. PepGen's return on equity of -59.89% beat CervoMed's return on equity. Company Net Margins Return on Equity Return on Assets CervoMed -672.80% -136.08% -112.62% PepGen N/A -59.89% -49.62%

Does the media refer more to CRVO or PEPG?

In the previous week, CervoMed had 1 more articles in the media than PepGen. MarketBeat recorded 3 mentions for CervoMed and 2 mentions for PepGen. CervoMed's average media sentiment score of 0.00 equaled PepGen'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CervoMed 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PepGen 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend CRVO or ORMP?

CervoMed presently has a consensus target price of $22.60, indicating a potential upside of 710.04%. Given CervoMed's stronger consensus rating and higher probable upside, equities research analysts clearly believe CervoMed is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CervoMed 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend TLSA or CRVO?

CervoMed has a consensus target price of $22.60, suggesting a potential upside of 710.04%. Given CervoMed's stronger consensus rating and higher probable upside, analysts clearly believe CervoMed is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 CervoMed 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63

Which has higher valuation and earnings, TLSA or CRVO?

Tiziana Life Sciences has higher earnings, but lower revenue than CervoMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tiziana Life Sciences N/A N/A -$18.43M N/A N/A CervoMed $4.01M 9.41 -$26.97M -$3.28 N/A

Does the media favor TLSA or CRVO?

In the previous week, CervoMed had 1 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 3 mentions for CervoMed and 2 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 1.05 beat CervoMed's score of 0.00 indicating that Tiziana Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tiziana Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CervoMed 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ACB or CRVO?

CervoMed has a consensus price target of $22.60, indicating a potential upside of 710.04%. Given CervoMed's stronger consensus rating and higher probable upside, analysts clearly believe CervoMed is more favorable than Aurora Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurora Cannabis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 CervoMed 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63

Is ACB or CRVO more profitable?

Aurora Cannabis has a net margin of -33.57% compared to CervoMed's net margin of -672.80%. Aurora Cannabis' return on equity of 0.10% beat CervoMed's return on equity. Company Net Margins Return on Equity Return on Assets Aurora Cannabis -33.57% 0.10% 0.07% CervoMed -672.80% -136.08% -112.62%

Does the media refer more to CRVO or MIST?

In the previous week, CervoMed had 1 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 3 mentions for CervoMed and 2 mentions for Milestone Pharmaceuticals. Milestone Pharmaceuticals' average media sentiment score of 1.51 beat CervoMed's score of 0.00 indicating that Milestone Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CervoMed 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Milestone Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

CervoMed (CRVO) Competitors

$2.79 -0.29 (-9.42%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$2.90 +0.12 (+4.12%)

As of 06:34 AM Eastern

Compare

CRVO vs. PEPG, ORMP, TLSA, ACB, and MIST

Should you buy CervoMed stock or one of its competitors? MarketBeat compares CervoMed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CervoMed include PepGen (PEPG), Oramed Pharmaceuticals (ORMP), Tiziana Life Sciences (TLSA), Aurora Cannabis (ACB), and Milestone Pharmaceuticals (MIST). These companies are all part of the "pharmaceutical products" industry.

How does CervoMed compare to PepGen?

CervoMed (NASDAQ:CRVO) and PepGen (NASDAQ:PEPG) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

CervoMed has a beta of -0.68, indicating that its share price is 168% less volatile than the broader market. Comparatively, PepGen has a beta of 1.88, indicating that its share price is 88% more volatile than the broader market.

CervoMed has higher revenue and earnings than PepGen. PepGen is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	$4.01M	9.41	-$26.97M	-$3.28	N/A
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A

25.2% of CervoMed shares are held by institutional investors. Comparatively, 58.0% of PepGen shares are held by institutional investors. 35.8% of CervoMed shares are held by company insiders. Comparatively, 1.3% of PepGen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

CervoMed presently has a consensus price target of $22.60, suggesting a potential upside of 710.04%. PepGen has a consensus price target of $11.50, suggesting a potential upside of 422.73%. Given CervoMed's higher possible upside, analysts clearly believe CervoMed is more favorable than PepGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

PepGen has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. PepGen's return on equity of -59.89% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CervoMed	-672.80%	-136.08%	-112.62%
PepGen	N/A	-59.89%	-49.62%

In the previous week, CervoMed had 1 more articles in the media than PepGen. MarketBeat recorded 3 mentions for CervoMed and 2 mentions for PepGen. CervoMed's average media sentiment score of 0.00 equaled PepGen'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CervoMed	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PepGen	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

PepGen beats CervoMed on 7 of the 13 factors compared between the two stocks.

How does CervoMed compare to Oramed Pharmaceuticals?

CervoMed (NASDAQ:CRVO) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

25.2% of CervoMed shares are owned by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 35.8% of CervoMed shares are owned by company insiders. Comparatively, 17.8% of Oramed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

CervoMed presently has a consensus target price of $22.60, indicating a potential upside of 710.04%. Given CervoMed's stronger consensus rating and higher probable upside, equities research analysts clearly believe CervoMed is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Oramed Pharmaceuticals has lower revenue, but higher earnings than CervoMed. CervoMed is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	$4.01M	9.41	-$26.97M	-$3.28	N/A
Oramed Pharmaceuticals	$2M	83.91	$64.05M	$2.59	1.58

In the previous week, CervoMed had 3 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 3 mentions for CervoMed and 0 mentions for Oramed Pharmaceuticals. CervoMed's average media sentiment score of 0.00 equaled Oramed Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
CervoMed	Neutral
Oramed Pharmaceuticals	Neutral

Oramed Pharmaceuticals has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. Oramed Pharmaceuticals' return on equity of -5.37% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CervoMed	-672.80%	-136.08%	-112.62%
Oramed Pharmaceuticals	N/A	-5.37%	-4.83%

CervoMed has a beta of -0.68, meaning that its stock price is 168% less volatile than the broader market. Comparatively, Oramed Pharmaceuticals has a beta of 1.21, meaning that its stock price is 21% more volatile than the broader market.

Summary

Oramed Pharmaceuticals beats CervoMed on 8 of the 15 factors compared between the two stocks.

How does CervoMed compare to Tiziana Life Sciences?

Tiziana Life Sciences (NASDAQ:TLSA) and CervoMed (NASDAQ:CRVO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

In the previous week, CervoMed had 1 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 3 mentions for CervoMed and 2 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 1.05 beat CervoMed's score of 0.00 indicating that Tiziana Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tiziana Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CervoMed	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

25.2% of CervoMed shares are owned by institutional investors. 39.8% of Tiziana Life Sciences shares are owned by insiders. Comparatively, 35.8% of CervoMed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Tiziana Life Sciences has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. Tiziana Life Sciences' return on equity of 0.00% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tiziana Life Sciences	N/A	N/A	N/A
CervoMed	-672.80%	-136.08%	-112.62%

CervoMed has a consensus target price of $22.60, suggesting a potential upside of 710.04%. Given CervoMed's stronger consensus rating and higher probable upside, analysts clearly believe CervoMed is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tiziana Life Sciences	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
CervoMed	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Tiziana Life Sciences has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market. Comparatively, CervoMed has a beta of -0.68, meaning that its stock price is 168% less volatile than the broader market.

Tiziana Life Sciences has higher earnings, but lower revenue than CervoMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A
CervoMed	$4.01M	9.41	-$26.97M	-$3.28	N/A

Summary

Tiziana Life Sciences beats CervoMed on 7 of the 13 factors compared between the two stocks.

How does CervoMed compare to Aurora Cannabis?

Aurora Cannabis (NASDAQ:ACB) and CervoMed (NASDAQ:CRVO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Aurora Cannabis has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market. Comparatively, CervoMed has a beta of -0.68, meaning that its stock price is 168% less volatile than the broader market.

Aurora Cannabis has a net margin of -33.57% compared to CervoMed's net margin of -672.80%. Aurora Cannabis' return on equity of 0.10% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurora Cannabis	-33.57%	0.10%	0.07%
CervoMed	-672.80%	-136.08%	-112.62%

CervoMed has lower revenue, but higher earnings than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurora Cannabis	$247.82M	0.64	-$88.13M	-$1.56	N/A
CervoMed	$4.01M	9.41	-$26.97M	-$3.28	N/A

CervoMed has a consensus price target of $22.60, indicating a potential upside of 710.04%. Given CervoMed's stronger consensus rating and higher probable upside, analysts clearly believe CervoMed is more favorable than Aurora Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurora Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CervoMed	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

47.6% of Aurora Cannabis shares are held by institutional investors. Comparatively, 25.2% of CervoMed shares are held by institutional investors. 0.0% of Aurora Cannabis shares are held by insiders. Comparatively, 35.8% of CervoMed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, CervoMed had 3 more articles in the media than Aurora Cannabis. MarketBeat recorded 3 mentions for CervoMed and 0 mentions for Aurora Cannabis. Aurora Cannabis' average media sentiment score of 0.00 equaled CervoMed'saverage media sentiment score.

Company	Overall Sentiment
Aurora Cannabis	Neutral
CervoMed	Neutral

Summary

CervoMed beats Aurora Cannabis on 8 of the 15 factors compared between the two stocks.

How does CervoMed compare to Milestone Pharmaceuticals?

CervoMed (NASDAQ:CRVO) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Milestone Pharmaceuticals has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. CervoMed's return on equity of -136.08% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CervoMed	-672.80%	-136.08%	-112.62%
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%

CervoMed currently has a consensus target price of $22.60, indicating a potential upside of 710.04%. Milestone Pharmaceuticals has a consensus target price of $7.25, indicating a potential upside of 514.41%. Given CervoMed's higher possible upside, analysts plainly believe CervoMed is more favorable than Milestone Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

25.2% of CervoMed shares are owned by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 35.8% of CervoMed shares are owned by insiders. Comparatively, 5.0% of Milestone Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

CervoMed has a beta of -0.68, indicating that its share price is 168% less volatile than the broader market. Comparatively, Milestone Pharmaceuticals has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

CervoMed has higher revenue and earnings than Milestone Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	$4.01M	9.41	-$26.97M	-$3.28	N/A
Milestone Pharmaceuticals	$1.55M	94.78	-$63.06M	-$0.68	N/A

In the previous week, CervoMed had 1 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 3 mentions for CervoMed and 2 mentions for Milestone Pharmaceuticals. Milestone Pharmaceuticals' average media sentiment score of 1.51 beat CervoMed's score of 0.00 indicating that Milestone Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CervoMed	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Milestone Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Milestone Pharmaceuticals beats CervoMed on 9 of the 17 factors compared between the two stocks.

Get CervoMed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRVO vs. The Competition

Export

Metric	CervoMed	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$41.66M	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-0.85	20.49	27.07	23.94
Price / Sales	9.41	300.33	512.71	90.33
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	1.42	7.92	10.63	6.14
Net Income	-$26.97M	$23.81M	$3.60B	$331.74M
7 Day Performance	-9.42%	-1.09%	-1.24%	-1.82%
1 Month Performance	-34.20%	2.56%	1.09%	-1.45%
1 Year Performance	-66.90%	42.16%	23.66%	16.32%

CervoMed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRVO CervoMed	2.8713 of 5 stars	$2.79 -9.4%	$22.60 +710.0%	-62.3%	$41.66M	$4.01M	N/A	4
PEPG PepGen	1.8673 of 5 stars	$2.43 -0.3%	$11.50 +372.9%	+63.0%	$168.29M	N/A	N/A	30	News Coverage
ORMP Oramed Pharmaceuticals	1.5834 of 5 stars	$4.05 +2.4%	N/A	+93.4%	$165.56M	$2M	1.56	10
TLSA Tiziana Life Sciences	0.7423 of 5 stars	$1.31 -1.9%	N/A	-34.5%	$165.44M	N/A	N/A	8	Positive News
ACB Aurora Cannabis	0.9593 of 5 stars	$2.69 +0.6%	N/A	-42.8%	$164.70M	$247.82M	N/A	1,028

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRVO) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CervoMed (CRVO) Competitors

CRVO vs. PEPG, ORMP, TLSA, ACB, and MIST

How does CervoMed compare to PepGen?

Summary

How does CervoMed compare to Oramed Pharmaceuticals?

Summary

How does CervoMed compare to Tiziana Life Sciences?

Summary

How does CervoMed compare to Aurora Cannabis?

Summary

How does CervoMed compare to Milestone Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVO vs. The Competition

CervoMed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CervoMed (CRVO) Competitors

CRVO vs. PEPG, ORMP, TLSA, ACB, and MIST

How does CervoMed compare to PepGen?

Which has more volatility and risk, CRVO or PEPG?

Which has stronger valuation & earnings, CRVO or PEPG?

Do institutionals & insiders hold more shares of CRVO or PEPG?

Do analysts prefer CRVO or PEPG?

Is CRVO or PEPG more profitable?

Does the media refer more to CRVO or PEPG?

Summary

How does CervoMed compare to Oramed Pharmaceuticals?

Do institutionals and insiders believe in CRVO or ORMP?

Do analysts recommend CRVO or ORMP?

Which has preferable earnings & valuation, CRVO or ORMP?

Does the media refer more to CRVO or ORMP?

Is CRVO or ORMP more profitable?

Which has more risk and volatility, CRVO or ORMP?

Summary

How does CervoMed compare to Tiziana Life Sciences?

Does the media favor TLSA or CRVO?

Do institutionals and insiders hold more shares of TLSA or CRVO?

Is TLSA or CRVO more profitable?

Do analysts recommend TLSA or CRVO?

Which has more risk & volatility, TLSA or CRVO?

Which has higher valuation and earnings, TLSA or CRVO?

Summary

How does CervoMed compare to Aurora Cannabis?

Which has more risk & volatility, ACB or CRVO?

Is ACB or CRVO more profitable?

Which has better valuation and earnings, ACB or CRVO?

Do analysts rate ACB or CRVO?

Do institutionals and insiders believe in ACB or CRVO?

Does the media prefer ACB or CRVO?

Summary

How does CervoMed compare to Milestone Pharmaceuticals?

Is CRVO or MIST more profitable?

Do analysts prefer CRVO or MIST?

Do insiders and institutionals have more ownership in CRVO or MIST?

Which has more volatility and risk, CRVO or MIST?

Which has stronger valuation and earnings, CRVO or MIST?

Does the media refer more to CRVO or MIST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRVO vs. The Competition

CervoMed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools